#Janssen Therapeutics

The FDA recently held up the U.S. approval based on concerns over the monthly injectable regimen’s manufacturing.

Advocates claim Gilead and others unfairly limited competition for HIV combination pills.

Long-acting injectables may be given once every other month, according to new findings.

This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.

Calling all U.S. cisgender gay and bi men and trans and gender nonconforming people at risk for the virus.

Class action lawsuit challenges deals that limit generic drug competition; Gilead says the case is without merit.

Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.

The Mosaico study will enroll gay and bisexual men and transgender people at significant risk for the virus.

Given every four weeks, the combo injection of cabotegravir and Edurant (rilpivirine) will likely face an FDA decision by early 2020.

The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.

A machine learning algorithm designed small sets of proteins that boasted the greatest potential to elicit a broad-based immune response.

Pharma giants made agreements to keep prices high and block competition for generics, the civil lawsuit alleges.

Dosed every four weeks, the injection, which requires a clinic visit, includes long-acting rilpivirine and cabotegravir.

Researchers enrolled participants within 14 days of their HIV diagnosis.